JOURNAL CULTUREL GRAFFICIBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL CULTUREL GRAFFICI
Company Title:
Company Description:
Keywords to Search:
Company Address:	200 Boul Perron O #B,NEW RICHMOND,QC,Canada
ZIP Code: Postal Code:	G0C2B0
Telephone Number:	4183927440
Fax Number:	8199941469
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	2711-01
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	5 to 9
Sales Amount:	$1 to 2.5 million
Credit History: Credit Report:	Very Good
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JOURNAL LE GOELAND
JOURNAL LECHO DE LA BAIE
JOURNAL CULTUREL GRAFFICI

Next company profile:
JOURNAL CULTUREL GRAFFICI
JEAN COUTU
J A CORMIER & FILS INC

Company News:

Recently Published - The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Preclinical and observational studies suggest that exercise may improve cancer outcomes However, definitive level 1 evidence is lacking In this phase 3, randomized trial conducted at 55 centers,
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Uncontrolled hypertension remains a leading cause of cardiovascular complications and death from cardiovascular disease 1 Despite the use of multidrug regimens, reaching recommended blood
Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
VITT-like Monoclonal Gammopathy of Thrombotic Significance
Anti‐ PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT ‐like and VITT ‐like characteristics , British Journal of Haematology